Beth A Overmoyer

Beth A Overmoyer

UNVERIFIED PROFILE

Are you Beth A Overmoyer?   Register this Author

Register author
Beth A Overmoyer

Beth A Overmoyer

Publications by authors named "Beth A Overmoyer"

Are you Beth A Overmoyer?   Register this Author

15Publications

416Reads

21Profile Views

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

N Engl J Med 2015 Jan;372(2):134-41

From the Departments of Medical Oncology (S.M.T., B.A.O., A.H.P., I.E.K., H.J.B., E.P.W.) and Biostatistics and Computation Biology (W.T.B., H.G.), Dana-Farber Cancer Institute, and Department of Hematology-Oncology, Massachusetts General Hospital (B.M.) - both in Boston; Breast Cancer Medicine Service, Department of Medicine, Solid Tumor Division, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Weill Cornell Medical Center, New York (C.T.D., C.A.H.), and Department of Medical Oncology, Hofstra North Shore-LIJ School of Medicine, New Hyde Park (I.S.) - all in New York; Sarah Cannon Cancer Center, Department of Medical Oncology, Nashville (D.A.Y.); Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham (P.K.M.), and Department of Medical Oncology, University of North Carolina, Chapel Hill (L.A.C.) - both in North Carolina; Cardinal Bernardin Cancer Center, Department of Medicine, Division of Hematology-Oncology, Loyola University Chicago Stritch School of Medicine, Maywood, IL (K.S.A.); Comprehensive Cancer Center, Department of Medicine, Division of Oncology, University of California, San Francisco, San Francisco (H.S.R.); Department of Medical Oncology, Washington University in St. Louis, St. Louis (M.E.); and Johns Hopkins Kimmel Cancer Center, Department of Oncology, Baltimore (A.C.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1406281DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313867PMC
January 2015

Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.

Ann Surg Oncol 2013 Mar 7;20(3):811-8. Epub 2012 Sep 7.

Department of Radiation Oncology, Brigham & Women's Hospital/Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1245/s10434-012-2640-8
Publisher Site
http://dx.doi.org/10.1245/s10434-012-2640-8DOI Listing
March 2013

Case records of the Massachusetts General Hospital. Case 17-2011. A 49-year-old woman with a mass in the breast and overlying skin changes.

N Engl J Med 2011 Jun;364(23):2246-54

Department of Medical Oncology, Dana–Farber Cancer Institute, Boston, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMcpc1100922DOI Listing
June 2011

Inflammatory breast cancer: novel preoperative therapies.

Authors:
Beth A Overmoyer

Clin Breast Cancer 2010 Feb;10(1):27-32

Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2010.n.003DOI Listing
February 2010